Artrya (ASX: AYA) Secures Fifth US Hospital Deal as Commercial Momentum Builds in $580 Million Growth Story

Artrya Limited (ASX: AYA) is gaining momentum in the US healthcare market, securing a five-year agreement with Arizona-based HonorHealth worth at least US$500,000.

The 13 November announcement marks an important commercial milestone. HonorHealth becomes Artrya's fifth US commercial customer and its first secured through inbound engagement outside its foundation hospital partnerships and SAPPHIRE research program.

For a medical technology company developing artificial intelligence solutions for cardiac imaging, this signals growing recognition of its technology and a potentially broader pathway to recurring revenue.

Key Numbers

• US$500,000: Minimum contracted value of the five-year HonorHealth agreement.
• 5: US commercial customers secured following the latest agreement.
• 9 hospitals: HonorHealth's acute-care network across Phoenix and Scottsdale.
• $67.2 million: Cash and term deposits at 30 September 2026.
• $84,000: September-quarter customer receipts, alongside $6.82 million in net operating cash outflow.

The Latest Development

HonorHealth will implement Artrya's Salix platform, which uses artificial intelligence to analyse coronary CT angiography scans and help clinicians assess coronary artery disease.

The agreement provides recurring subscription revenue through Salix Coronary Anatomy, alongside opportunities for additional usage-based revenue.

What makes this agreement particularly encouraging is how HonorHealth became a customer.

Unlike previous hospital relationships developed through research collaborations and foundation partnerships, HonorHealth represents an independent commercial opportunity.

This suggests Artrya's technology is beginning to attract attention beyond its established clinical network.

The minimum agreement value equates to US$100,000 annually over five years, with potential additional revenue depending on product utilisation and deployment.

HonorHealth's nine-hospital network also provides an opportunity for broader adoption, although the agreement does not guarantee immediate deployment across every facility.

What Stands Out to Us

Artrya is building a potentially scalable commercial model through recurring software subscriptions and usage-based revenue.

As hospitals increase scan volumes and adopt additional Salix capabilities, revenue could grow within existing customer relationships without requiring equivalent increases in customer acquisition.

Its FDA-cleared Coronary Anatomy and Coronary Plaque products provide an important foundation for commercial expansion.

Financially, Artrya remains in an investment phase, with September-quarter operating cash outflow of $6.82 million.

However, its $67.2 million liquidity position provides considerable flexibility to support US expansion, product development and commercial deployment.

Based on approximately $6.9 million in quarterly net cash consumption, this represents around 9.8 quarters of funding at the historical expenditure rate.

At its 12 November closing share price of $3.44, Artrya's market capitalisation was approximately $580 million.

We believe this valuation reflects expectations of significant future growth, making successful commercial execution increasingly important.

What the Company Is Doing Now

Artrya is accelerating its US commercialisation strategy by converting clinical partnerships into paying customer relationships and expanding deployments across existing hospital networks.

Its October agreement with Huntsville Hospital Health System demonstrated progress in converting research relationships into commercial contracts.

Northeast Georgia Health System is expanding beyond its initial deployment, while Cone Health continues progressing towards clinical implementation.

At Tanner Health, improvements to reimbursement pre-authorisation processes have supported increased Coronary Plaque utilisation.

Artrya is also advancing clinical validation for its Salix Coronary Flow technology, with further work required before its planned FDA submission.

Together, these initiatives could expand Artrya's addressable commercial opportunity while strengthening its position in AI-assisted cardiac imaging.

Insight: Is Artrya Building a Scalable US Healthcare Business?

We see HonorHealth as an encouraging indication that Artrya's commercial strategy is gaining traction beyond its original hospital partnerships. Its FDA-cleared technology, recurring revenue model and substantial cash reserves provide a promising foundation for expansion. Importantly, each new hospital relationship creates opportunities for greater product utilisation and additional revenue over time. While commercial receipts remain modest relative to operating expenditure, we believe Artrya is establishing the infrastructure needed for longer-term growth. Sustained increases in clinical adoption and recurring revenue would provide stronger evidence supporting its current valuation.

What Happens Next?

The next phase will focus on implementing Salix at HonorHealth, increasing utilisation across existing customers and progressing the regulatory pathway for Coronary Flow.

Artrya's estimated $4.8 million research and development tax rebate, expected in early 2027, could also strengthen its funding position.

The most important measure will be whether expanding hospital adoption produces accelerating customer receipts and recurring revenue.

With five US commercial customers secured, growing recognition of its technology and a substantial liquidity position, Artrya is establishing a stronger platform for commercial growth.

The opportunity now lies in translating that expanding clinical footprint into sustainable financial performance.